Host Tissue Damage by Phagocytes
暂无分享,去创建一个
[1] G. Ricevuti,et al. The Pathophysiology of Phagocytes , 1989 .
[2] Z. M. Chen,et al. Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents. , 1990, The American journal of physiology.
[3] W. Weintraub,et al. Elevation of C-reactive protein in "active" coronary artery disease. , 1990, The American journal of cardiology.
[4] D. Lanier,et al. Reduction by cimetidine of serum parathyroid hormone levels in uremic patients. , 1980, The New England journal of medicine.
[5] J. Mehta,et al. Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. , 1990, Journal of the American College of Cardiology.
[6] F. Rickles,et al. The role of leukocytes in the activation of blood coagulation. , 1992, Seminars in hematology.
[7] R. Tuma,et al. Factors Influencing Leukocyte Adherence in Microvessels , 1977, Thrombosis and Haemostasis.
[8] G. Mandell,et al. Polymorphonuclear leukocytes: dedicated professional phagocytes. , 1983, The American journal of medicine.
[9] G. Ricevuti,et al. Membrane Glycoproteins in Superoxide Release from Neutrophils , 1990 .
[10] G. Specchia,et al. Increased Expression of Neutrophil and Monocyte Adhesion Molecules in Unstable Coronary Artery Disease , 1993, Circulation.
[11] R. Faint. Platelet-neutrophil interactions: their significance. , 1992, Blood reviews.
[12] J. White,et al. Platelet activation by fMLP-stimulated polymorphonuclear leukocytes: the activity of cathepsin G is not prevented by antiproteinases. , 1991, Blood.
[13] B. Smith,et al. Activated and unactivated platelet adhesion to monocytes and neutrophils. , 1991, Blood.
[14] E. Engvall,et al. Enzyme-linked immunosorbent assay. II. Quantitative assay of protein antigen, immunoglobulin G, by means of enzyme-labelled antigen and antibody-coated tubes. , 1971, Biochimica et biophysica acta.
[15] N. Benowitz. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction. , 1988, The New England journal of medicine.
[16] P. Venge,et al. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. , 1992, The Journal of thoracic and cardiovascular surgery.
[17] H. Jacob,et al. Cholesterol and atheroma lipids activate complement and stimulate granulocytes. A possible mechanism for amplification of ischemic injury in atherosclerotic states. , 1981, The Journal of laboratory and clinical medicine.
[18] W. Hörl,et al. Neutrophil activation in acute renal failure and sepsis. , 1990, Archives of surgery.
[19] M. Curtis,et al. Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease. , 1993, Cardiovascular research.
[20] G. Schmid-Schönbein,et al. Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. , 1986, The American journal of physiology.
[21] W. Dreyer,et al. Neutrophil adherence to isolated adult canine myocytes. Evidence for a CD18-dependent mechanism. , 1990, The Journal of clinical investigation.
[22] E. Dejana,et al. Platelet-neutrophil interactions. Possible relevance in the pathogenesis of thrombosis and inflammation. , 1991, Haematologica.
[23] G. Ricevuti,et al. Definition of CD 11a, b, c, and CD 18 glycoproteins on chemotactically deficient granulocyte membranes in patients affected by myeloid disorders. , 1989, Acta haematologica.
[24] M. Klempner,et al. The effect of hemodialysis and C5a des arg on neutrophil subpopulations. , 1980, Blood.
[25] G. Specchia,et al. Granulocyte function in coronary artery disease. , 1991, The American journal of cardiology.
[26] Rickles Fr,et al. The role of leukocytes in the activation of blood coagulation. , 1992 .
[27] R. Guidoin,et al. Effects of thrombocytopenia and shear rate on neutrophil and platelet deposition on endothelial and medial arterial surfaces. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[28] S. Abramson,et al. The neutrophil in rheumatoid arthritis. , 1995, Rheumatic diseases clinics of North America.
[29] P. Fratino,et al. New trends in coronary artery disease: the role of granulocyte activation. , 1989, Atherosclerosis.
[30] Robert A. Lewis,et al. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. , 1990, The New England journal of medicine.
[31] H. Makker,et al. Mechanisms of exercise‐induced asthma , 1994, European journal of clinical investigation.
[32] M. Boogaerts,et al. Enhancement of granulocyte-endothelial cell adherence and granulocyte-induced cytotoxicity by platelet release products. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Covell,et al. Granulocytes cause reperfusion ventricular dysfunction after 15-minute ischemia in the dog. , 1987, Circulation research.
[34] S. Neumann,et al. “PMN-Elastase Assay”: Enzyme Immunoassay for Human Polymorphonuclear Elastase Complexed with α1-Proteinase Inhibitor , 1984, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.
[35] J I Gallin,et al. Current concepts: immunology. Neutrophils in human diseases. , 1987, The New England journal of medicine.
[36] Cell Adhesion Molecules and the Kidney , 1994 .
[37] G. Specchia,et al. Granulocyte activation after coronary angioplasty in humans. , 1990, Circulation.
[38] G. Ricevuti,et al. The Biology of phagocytes in health and disease , 1987 .
[39] A. Böyum,et al. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.
[40] P. Serruys,et al. Effect of coronary occlusion during percutaneous transluminal angioplasty in humans on left ventricular chamber stiffness and regional diastolic pressure-radius relations. , 1986, Journal of the American College of Cardiology.
[41] B. Babior,et al. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. , 1973, The Journal of clinical investigation.
[42] P. Venge,et al. Inflammatory system activation during cardiopulmonary bypass as an indicator of biocompatibility: a randomized comparison of bubble and membrane oxygenators. , 1990, Scandinavian journal of thoracic and cardiovascular surgery.
[43] E. Braunwald,et al. The Stunned Myocardium: Prolonged, Postischemic Ventricular Dysfunction , 1982, Circulation.
[44] J. Harlan. Consequences of Leukocyte-Vessel Wall Interactions in Inflammatory and Immune Reactions , 1987, Seminars in thrombosis and hemostasis.
[45] M. Cohen,et al. A defect in the oxidative metabolism of human polymorphonuclear leukocytes that remain in circulation early in hemodialysis. , 1982, Blood.
[46] E. Plow. Leukocyte elastase release during blood coagulation. A potential mechanism for activation of the alternative fibrinolytic pathway. , 1982, The Journal of clinical investigation.
[47] S. Werns,et al. Leukocytes, oxygen radicals, and myocardial injury due to ischemia and reperfusion. , 1988, Free radical biology & medicine.
[48] D. D. de Bono. Free radicals and antioxidants in vascular biology: the roles of reaction kinetics, environment and substrate turnover. , 1994, QJM : monthly journal of the Association of Physicians.
[49] G. Ronquist,et al. Bubble and membrane oxygenators--comparison of postoperative organ dysfunction with special reference to inflammatory activity. , 1990, Scandinavian journal of thoracic and cardiovascular surgery.
[50] J. Baars,et al. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. , 1992, British Journal of Cancer.
[51] G. Camussi,et al. The release of platelet-activating factor from human endothelial cells in culture. , 1983, Journal of immunology.
[52] S. Weiss. Tissue destruction by neutrophils. , 1989, The New England journal of medicine.
[53] S. de Servi,et al. Granulocytes and Myocardial Ischemia , 1989 .
[54] J. Mehta,et al. Neutrophil function in ischemic heart disease. , 1989, Circulation.
[55] B. Månsson,et al. Cytidine deaminase activity in synovial fluid of patients with rheumatoid arthritis: relation to lactoferrin, acidosis, and cartilage proteoglycan release. , 1990, Annals of the rheumatic diseases.
[56] G. Specchia,et al. Role of granulocytes in endothelial injury in coronary heart disease in humans. , 1991, Atherosclerosis.
[57] S. Berliner,et al. The leukergy test in patients with ischemic heart disease. , 1986, American heart journal.
[58] R. Snyderman,et al. Activation of the respiratory burst enzyme in human polymorphonuclear leukocytes by chemoattractants and other soluble stimuli. Evidence that the same oxidase is activated by different transductional mechanisms. , 1983, The Journal of clinical investigation.
[59] B. Lucchesi. Role of neutrophils in ischemic heart disease: pathophysiologic role in myocardial ischemia and coronary artery reperfusion. , 1987, Cardiovascular clinics.
[60] L. Harker,et al. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. , 1987, The American journal of cardiology.
[61] E. Jaffe,et al. Human leukocyte cathepsin G and elastase specifically suppress thrombin-induced prostacyclin production in human endothelial cells. , 1989, Blood.
[62] D. Altieri,et al. Coagulation assembly on leukocytes in transmembrane signaling and cell adhesion. , 1993, Blood.
[63] G. Weissmann,et al. Release of inflammatory mediators from stimulated neutrophils. , 1980, The New England journal of medicine.
[64] G. Specchia,et al. Clinical and angiographic correlates of leukocyte activation in unstable angina. , 1995, Journal of the American College of Cardiology.
[65] S. Popoff,et al. Animal models of osteopetrosis: the impact of recent molecular developments on novel strategies for therapeutic intervention. , 1996, Molecular medicine today.
[66] H. Broxmeyer,et al. Regulation of human bone marrow lactoferrin and myeloperoxidase gene expression by tumor necrosis factor-alpha. , 1991, Journal of immunology.
[67] M. J. Moore,et al. Complement-induced granulocyte aggregation: an unsuspected mechanism of disease. , 1980, The New England journal of medicine.
[68] B. Diamond,et al. Autoimmunity in heart disease: mechanisms and genetic susceptibility. , 1996, Molecular medicine today.
[69] V. Fuster,et al. Restenosis after arterial angioplasty: a hemorrheologic response to injury. , 1987, The American journal of cardiology.
[70] A. Bøyum,et al. Isolation of mononuclear cells and granulocytes from human blood. , 1968 .
[71] J. V. van Mourik,et al. Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin-stimulated endothelial cells. , 1990, Journal of immunology.
[72] E. C. Slater,et al. The extinction coefficient of cytochrome c. , 1962, Biochimica et biophysica acta.
[73] J. Harlan. Leukocyte-endothelial interactions. , 1985, Blood.
[74] K. Przyklenk. Oxygen-derived free radicals and 'stunned myocardium'. , 1988, Free radical biology & medicine.
[75] G. Specchia,et al. Increased neutrophil aggregability in coronary artery disease. , 1990, European heart journal.
[76] G. Specchia,et al. Transcardiac release of leukotriene C4 by neutrophils in patients with coronary artery disease. , 1991, Journal of the American College of Cardiology.
[77] B. Brando,et al. Nationwide quality control trial on lymphocyte immunophenotyping and flow cytometer performance in Italy. , 1993, Cytometry.
[78] R E Vlietstra,et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. , 1984, The American journal of cardiology.